NeuBase Therapeutics, Inc.

Equities

NBSE

US64132K2015

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-10 pm EDT			5-day change	1st Jan Change
0.378 ^USD	-3.20%		-6.67%	-48.93%

Mar. 26	Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	MT
Mar. 26	US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings	MT

NeuBase Therapeutics, Inc. Announces Resignation of William Mann as President and Chief Operating Officer, Effective October 31, 2022

October 24, 2022 at 04:46 pm EDT

On October 18, 2022, William Mann, Ph.D., president and chief operating officer of NeuBase Therapeutics, Inc., notified the company of his intent to resign from the company, effective October 31, 2022. Dr. Mann's resignation is not a result of any disagreement with the company on any matter relating to the company's policies or procedures.

Latest news about NeuBase Therapeutics, Inc.

Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	Mar. 26	MT
US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings	Mar. 26	MT
Top Premarket Decliners	Mar. 26	MT
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
North American Morning Briefing : Investors -2-	Mar. 18	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
North American Morning Briefing : Traders Await -2-	Feb. 26	DJ
NeuBase Therapeutics, Inc. Announces CEO Changes	Jan. 17	CI
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	Dec. 19	DJ
NeuBase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away	23-10-20	CI
Top Premarket Decliners	23-09-07	MT
Top Midday Gainers	23-09-06	MT
NEUBASE THERAPEUTICS SHARES UP 40% AFTER SYMETRYX CORPORATION AC…	23-09-06	RE
Top Premarket Gainers	23-09-06	MT
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
NeuBase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
NeuBase Therapeutics to Explore Strategic Alternatives	23-08-03	CI
NeuBase Therapeutics, Inc. announced that it has received $3.512751 million in funding	23-06-29	CI
NeuBase Therapeutics, Inc. Presents Non-Human Primate Data Illustrating Stealth Editors Are Non-Immunogenic, Opening the Door to Redosing	23-06-29	CI
NeuBase Therapeutics Launches $5 Million Registered Direct Offering, Concurrent Private Placement	23-06-28	MT
NeuBase Therapeutics, Inc. announced that it expects to receive $3.512751 million in funding	23-06-27	CI
NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from Russell 3000E Value Index	23-06-23	CI
NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from Russell Microcap Index	23-06-23	CI
NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from Russell Microcap Value Index	23-06-23	CI

Chart NeuBase Therapeutics, Inc.

Duration

Period

More charts

Company Profile

NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâs programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâs disease (HD), and oncology and in gene editing applications. It also focused on identifying and evaluating multiple indications for potential development.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Extraordinary Shareholders Meeting

More about the company

	1st Jan change	Capi.
NEUBASE THERAPEUTICS, INC.	-48.93%	1.42M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research